BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellectricon Release: A Fresh Approach to Developing Chronic Pain Therapeutics


5/29/2013 11:34:28 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Molndal, Sweden – 29 May 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be attending the 12th annual World Pharma Congress, 4 – 6 June (Philadelphia, PA). At the event, Cellectricon’s Head of Discovery Services, Dr Paul Karila, will host a presentation describing a novel phenotypic assay for the identification of therapeutic compounds for chronic pain. The talk, entitled ‘Development of a Phenotypic Pain Assay for Identification of Modulators of Excitability in Native Sensory Neurons’, will take place on Tues 4th June, 5pm, as part of the ‘Targeting Pain with Novel Therapeutics’ program.

This exciting new assay is based on the Cellaxess® technology platform, and uses electric field stimulation of primary DRG neuronal cultures to allow compound identification during early stages of the project lifecycle. As such, Dr Karila will explain how the approach can add significant value to the overall decision-making process of drug development, saving valuable time and cost.

Dr Paul Karila is Chairperson for the ‘Targeting Pain with Novel Therapeutics’ program, and will be on-hand throughout the day to answer any questions on Cellectricon’s services and technology. Alternatively, for more information on Cellectricon, please visit www.cellectricon.com

About Cellectricon

Cellectricon provides state-of-the-art discovery services and enabling technologies to accelerate drug discovery and cell-based research. Our compound profiling services in excitable cells and native tissue provide researchers with decision-making insight into the science of cytoskeletal disturbances, particularly focusing on chronic pain



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES